KAT7の加齢依存的な減少がiPS細胞由来血小板産生を阻害~免疫特性の促進を介したメカニズムを解明~

ad

2025-11-14 京都大学iPS細胞研究所

京都大学iPS細胞研究所(CiRA)の研究グループは、iPS細胞由来巨核球株(imMKCL)を用いた血小板大量製造技術において、加齢依存的に低下する酵素KAT7の機能低下が血小板産生能を阻害するメカニズムを解明しました。長期培養または老化モデル細胞ではG0期細胞が増加し、血小板産生に寄与するG1期・G2/M期細胞が減少していました。KAT7活性低下はセントロメア機能の不全を引き起こし、染色体不安定性を介してcGAS-STING経路が活性化、炎症性サイトカイン(TNF-αなど)の分泌が促進され、その結果G0期細胞の増加と血小板産生の抑制が進んでいました。本研究はKAT7を血小板製造の品質指標として提示し、iPS由来血小板の安定供給や再生医療製品の品質管理に向けた新たな知見を提供しています。

KAT7の加齢依存的な減少がiPS細胞由来血小板産生を阻害~免疫特性の促進を介したメカニズムを解明~
論文の概要図

<関連情報>

加齢に伴うKAT7/HBO1活性の低下は免疫特性を促進することでimMKCLベースの血小板産生を阻害する Aging-dependent reduction of KAT7/HBO1 activity impairs imMKCL-based platelet production by promoting immune properties

Wei-Yin Qiu ∙ Sou Nakamura ∙ Sudip Kumar Paul ∙ … ∙ Naoshi Sugimoto ∙ Si Jing Chen ∙ Koji Eto
Stem Cell Reports  November: 13, 2025
DOI:https://doi.org/10.1016/j.stemcr.2025.102714

Highlights

  • Cell cycle regulation at proliferation stage determines platelet producibility
  • Inhibition of KAT7 induces G0 arrest and immune phenotype dominance in imMKCLs
  • The dominance of immune megakaryocytes is mediated by cGAS-STING pathway
  • Pro-inflammatory cytokines released from imMKCLs could inhibit platelet production

Summary

The master cell bank (MCB) system is essential for regenerative cell therapy. We have developed induced pluripotent stem cell (iPSC)-based immortalized megakaryocyte progenitor cell lines (imMKCLs) as an MCB for iPSC-derived platelet (iPSC-PLT) transfusion. However, imMKCLs exhibit both thrombopoietic and immune-skewed properties, with enhanced immune activity impairing platelet production. The link between immune properties and thrombopoietic efficiency remains unclear. Here, we demonstrate that proliferating imMKCLs in G1 and G2/M interphases contribute to platelet generation, while lysine acetyltransferase 7 (KAT7) suppresses immune-biased dominancy to maintain these interphases. KAT7 inhibition with WM3835 increases G0 cells, mimicking imMKCL aging, and induces cGAS-STING activation, chromatin instability, and the secretion of tumor necrosis factor (TNF)-α, interferon (IFN)-β, and other pro-inflammatory cytokines. Additionally, TNF-α treatment recapitulates the transition to G0 seen with KAT7 loss. These findings identify KAT7 as a key regulator of imMKCL proliferation by preventing immune-skewed properties, highlighting its potential as a quality control marker in iPSC-PLT manufacturing.

医療・健康
ad
ad
Follow
ad
タイトルとURLをコピーしました